Bausch Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH
BAUSCH has one hundred and eighty-five approved drugs.
There are one hundred and eight US patents protecting BAUSCH drugs.
There are seven hundred and fifty-nine patent family members on BAUSCH drugs in fifty-four countries and two hundred and twenty-nine supplementary protection certificates in seventeen countries.
Summary for Bausch
| International Patents: | 759 |
| US Patents: | 108 |
| Tradenames: | 160 |
| Ingredients: | 125 |
| NDAs: | 185 |
| Patent Litigation for Bausch: | See patent lawsuits for Bausch |
Drugs and US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | NAFAZAIR | naphazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 040073-001 | May 25, 1994 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bausch | ALBUTEROL SULFATE | albuterol sulfate | SOLUTION;INHALATION | 075050-001 | Jun 18, 1998 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bausch And Lomb | PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168-001 | Apr 5, 2013 | AB | RX | Yes | Yes | 9,517,220 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | 8,084,047 | ⤷ Start Trial |
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | 8,784,789 | ⤷ Start Trial |
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | 7,910,767 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 0.04% | ➤ Subscribe | 2010-12-20 |
| ➤ Subscribe | Vaginal Gel | 0.75% | ➤ Subscribe | 2004-09-02 |
| ➤ Subscribe | Capsules | 75 mg | ➤ Subscribe | 2011-06-06 |
| ➤ Subscribe | Topical Solution | 10% | ➤ Subscribe | 2018-06-06 |
| ➤ Subscribe | Lotion | 0.1% | ➤ Subscribe | 2016-08-31 |
| ➤ Subscribe | Extended-release Tablets | 348 mg | ➤ Subscribe | 2009-09-24 |
| ➤ Subscribe | Cream | 3.75% | ➤ Subscribe | 2012-08-08 |
| ➤ Subscribe | Extended-release Tablets | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | ➤ Subscribe | 2005-08-30 |
| ➤ Subscribe | For Inhalation Solution | 6 gm/vial | ➤ Subscribe | 2014-05-22 |
| ➤ Subscribe | Extended-release Tablets | 65 mg and 115 mg | ➤ Subscribe | 2009-11-19 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 4mL pre-filled syringe | ➤ Subscribe | 2008-12-08 |
| ➤ Subscribe | Extended-release Tablet | 105 rng | ➤ Subscribe | 2010-12-28 |
| ➤ Subscribe | Gel | 1.2%/2.5% | ➤ Subscribe | 2012-12-20 |
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Gel | 0.1% | ➤ Subscribe | 2010-07-08 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
| ➤ Subscribe | Gel | 1.2%/0.025% | ➤ Subscribe | 2010-12-17 |
| ➤ Subscribe | Gel | 0.77% | ➤ Subscribe | 2006-05-10 |
| ➤ Subscribe | Cream | 5% | ➤ Subscribe | 2006-10-17 |
| ➤ Subscribe | Extended-release Tablets | 174 mg | ➤ Subscribe | 2009-09-28 |
| ➤ Subscribe | Cream | 0.10% | ➤ Subscribe | 2008-01-31 |
| ➤ Subscribe | Extended-release Tablets | 522 mg | ➤ Subscribe | 2009-12-24 |
| ➤ Subscribe | Cream | 2.5% | ➤ Subscribe | 2014-06-17 |
| ➤ Subscribe | Extended-release Tablets | 420 mg | ➤ Subscribe | 2005-04-25 |
| ➤ Subscribe | Rectal Gel | 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL | ➤ Subscribe | 2004-03-23 |
| ➤ Subscribe | Extended-release Tablet | 55 mg and 80 mg | ➤ Subscribe | 2010-12-02 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 2mL pre-filled syringe | ➤ Subscribe | 2008-12-23 |
| ➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2004-09-21 |
| ➤ Subscribe | Gel | 1.2%/3.75% | ➤ Subscribe | 2015-09-30 |
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
International Patents for Bausch Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | E027357 | ⤷ Start Trial |
| Australia | 2014329421 | ⤷ Start Trial |
| Poland | 2444079 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bausch Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2822954 | LUC00083 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| 1304992 | C300617 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322 |
| 1273292 | C01273292/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
